Resource Summary Report

Generated by FDI Lab - SciCrunch.org on Apr 6, 2025

Anti-METTL14 antibody produced in rabbit

RRID:AB_10672401
Type: Antibody

Proper Citation

(Sigma-Aldrich Cat# HPA038002, RRID:AB_10672401)

Antibody Information

URL: http://antibodyregistry.org/AB_10672401

Proper Citation: (Sigma-Aldrich Cat# HPA038002, RRID:AB_10672401)

Target Antigen: METTL14 antibody produced in rabbit

Host Organism: rabbit

Clonality: polyclonal

Comments: Vendor recommendations: immunohistochemistry (formalin-fixed, paraffin-embedded sections): suitable, protein array: suitable, immunoblotting: suitable; Immunohistochemistry; Other

Antibody Name: Anti-METTL14 antibody produced in rabbit

Description: This polyclonal targets METTL14 antibody produced in rabbit

Target Organism: human

Antibody ID: AB_10672401

Vendor: Sigma-Aldrich

Catalog Number: HPA038002

Record Creation Time: 20231110T070453+0000

Record Last Update: 20241114T233018+0000

Ratings and Alerts

- Antibody validation available from The Human Protein Atlas - Human Protein Atlas https://www.proteinatlas.org/search/HPA038002

No alerts have been found for Anti-METTL14 antibody produced in rabbit.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 31 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Pomaville M, et al. (2024) Small-molecule inhibition of the METTL3/METTL14 complex suppresses neuroblastoma tumor growth and promotes differentiation. Cell reports, 43(5), 114165.

Miyake K, et al. (2023) A cancer-associated METTL14 mutation induces aberrant m6A modification, affecting tumor growth. Cell reports, 42(7), 112688.

Mu M, et al. (2023) METTL14 regulates chromatin bivalent domains in mouse embryonic stem cells. Cell reports, 42(6), 112650.

He H, et al. (2023) METTL14 is decreased and regulates m6 A modification of ?-synuclein in Parkinson's disease. Journal of neurochemistry, 166(3), 609.

Li L, et al. (2023) Mettl14-mediated m6A modification ensures the cell-cycle progression of late-born retinal progenitor cells. Cell reports, 42(6), 112596.

Zhang J, et al. (2023) A lncRNA from the FTO locus acts as a suppressor of the m6A writer complex and p53 tumor suppression signaling. Molecular cell, 83(15), 2692.

Zhao Z, et al. (2023) QKI shuttles internal m7G-modified transcripts into stress granules and modulates mRNA metabolism. Cell, 186(15), 3208.

Zhang ZW, et al. (2022) METTL3 regulates m6A methylation of PTCH1 and GLI2 in Sonic hedgehog signaling to promote tumor progression in SHH-medulloblastoma. Cell reports, 41(4), 111530.

Niu F, et al. (2022) m6A regulation of cortical and retinal neurogenesis is mediated by the redundant m6A readers YTHDFs. iScience, 25(9), 104908.

Xu W, et al. (2022) Dynamic control of chromatin-associated m6A methylation regulates nascent RNA synthesis. Molecular cell, 82(6), 1156.

Du J, et al. (2022) N6-adenomethylation of GsdmC is essential for Lgr5+ stem cell survival to maintain normal colonic epithelial morphogenesis. Developmental cell, 57(16), 1976.

Chang M, et al. (2022) METTL3-mediated RNA m6A Hypermethylation Promotes Tumorigenesis and GH Secretion of Pituitary Somatotroph Adenomas. The Journal of clinical endocrinology and metabolism, 107(1), 136.

Li HB, et al. (2022) METTL14-mediated epitranscriptome modification of MN1 mRNA promote tumorigenicity and all-trans-retinoic acid resistance in osteosarcoma. EBioMedicine, 82, 104142.

Weng H, et al. (2022) The m6A reader IGF2BP2 regulates glutamine metabolism and represents a therapeutic target in acute myeloid leukemia. Cancer cell, 40(12), 1566.

Cao L, et al. (2022) METTL14-dependent m6A modification controls iNKT cell development and function. Cell reports, 40(5), 111156.

Cheng Y, et al. (2021) N6-Methyladenosine on mRNA facilitates a phase-separated nuclear body that suppresses myeloid leukemic differentiation. Cancer cell, 39(7), 958.

McFadden MJ, et al. (2021) Post-transcriptional regulation of antiviral gene expression by N6-methyladenosine. Cell reports, 34(9), 108798.

Cho S, et al. (2021) mTORC1 promotes cell growth via m6A-dependent mRNA degradation. Molecular cell, 81(10), 2064.

Ramalingam H, et al. (2021) A methionine-Mettl3-N6-methyladenosine axis promotes polycystic kidney disease. Cell metabolism, 33(6), 1234.

Gao Y, et al. (2020) m6A Modification Prevents Formation of Endogenous Double-Stranded RNAs and Deleterious Innate Immune Responses during Hematopoietic Development. Immunity, 52(6), 1007.